Enfusion (ENFN)
(Delayed Data from NYSE)
$8.92 USD
+0.03 (0.34%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $8.93 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.92 USD
+0.03 (0.34%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $8.93 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Zacks News
Enfusion (ENFN) Moves 5.0% Higher: Will This Strength Last?
by Zacks Equity Research
Enfusion (ENFN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Implied Volatility Surging for Enfusion (ENFN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Enfusion (ENFN) stock based on the movements in the options market lately.
Enfusion (ENFN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Enfusion (ENFN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Enfusion, Inc. (ENFN) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Enfusion (ENFN) delivered earnings and revenue surprises of -16.67% and 1.61%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
STNE or ENFN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
STNE vs. ENFN: Which Stock Is the Better Value Option?
Implied Volatility Surging for Enfusion (ENFN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Enfusion (ENFN) stock based on the movements in the options market lately.
Enfusion (ENFN) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Enfusion (ENFN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Radware (RDWR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Radware (RDWR) delivered earnings and revenue surprises of 14.29% and 2.34%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Enfusion, Inc. (ENFN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Enfusion, Inc. (ENFN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Enfusion, Inc. (ENFN) Lags Q4 Earnings Estimates
by Zacks Equity Research
Enfusion, Inc. (ENFN) delivered earnings and revenue surprises of -33.33% and 2.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Box (BOX) Q4 Earnings Beat Estimates
by Zacks Equity Research
Box (BOX) delivered earnings and revenue surprises of 10.53% and 0.02%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Phunware (PHUN): Can Its 75.3% Jump Turn into More Strength?
by Zacks Equity Research
Phunware (PHUN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Arteris, Inc. (AIP) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arteris, Inc. (AIP) delivered earnings and revenue surprises of -5.88% and 5.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
META or ENFN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
META vs. ENFN: Which Stock Is the Better Value Option?
Enfusion, Inc. (ENFN) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Enfusion, Inc. (ENFN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Unity Software Inc. (U) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Unity Software Inc. (U) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enfusion, Inc. (ENFN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Enfusion, Inc. (ENFN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Key Metrics Tell Us About Enfusion, Inc. (ENFN) Q2 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Enfusion, Inc. (ENFN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Enfusion, Inc. (ENFN) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Enfusion, Inc. (ENFN) delivered earnings and revenue surprises of -20% and 4.17%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Radware (RDWR) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Radware (RDWR) delivered earnings and revenue surprises of -28.57% and 5.19%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Olo Inc. (OLO): Can Its 6.3% Jump Turn into More Strength?
by Zacks Equity Research
Olo Inc. (OLO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
META vs. ENFN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
META vs. ENFN: Which Stock Is the Better Value Option?
Enfusion, Inc. (ENFN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Enfusion, Inc. (ENFN) closed the most recent trading day at $11.19, moving +1.36% from the previous trading session.
Enfusion, Inc. (ENFN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Enfusion, Inc. (ENFN) closed at $8.89, marking a -1% move from the previous day.
WIX Rolls Out Wix Shipping in Collaboration With Shippo
by Zacks Equity Research
WIX collaborates with Shippo to launch Wix Shipping, which will help business owners to effectively fulfill their eCommerce orders.